Sol-Gel Technologies Ltd. Logo

Sol-Gel Technologies Ltd.

Develops and commercializes topical dermatology drugs for acne, rosacea, and rare skin conditions.

SLGL | US

Overview

Corporate Details

ISIN(s):
IL0011417206
LEI:
Country:
United States of America
Address:
7 GOLDA MEIR ST., 7403648 NESS ZIONA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Sol-Gel Technologies Ltd. is a dermatology company engaged in the identification, development, and commercialization of topical drug products. The company has developed FDA-approved treatments, including Twyneo® for acne vulgaris and Epsolay® for inflammatory lesions of rosacea. Its clinical-stage pipeline focuses on delivering innovative treatments for rare skin conditions, with a lead candidate, patidegib gel, designed to prevent new basal cell carcinoma lesions in patients with Gorlin syndrome. Sol-Gel aims to address unmet patient needs by developing novel formulations that surpass the current standard of care in medical dermatology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Sol-Gel Technologies Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Sol-Gel Technologies Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Sol-Gel Technologies Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Gencurix Inc. Logo
Develops molecular diagnostic tests for cancer detection, prognosis, and treatment selection.
South Korea
229000
GENELUX Corp Logo
Developing oncolytic viral immunotherapies for difficult-to-treat cancers using a vaccinia virus.
United States of America
GNLX
GENEMATRIX INC. Logo
Develops multiplex PCR diagnostics and new drugs for infectious diseases like HPV and tuberculosis.
South Korea
109820
Genenta Science S.p.A. Logo
Develops cell & gene therapies using engineered stem cells to treat solid tumors.
United States of America
GNTA
GeneOne Life Science, Inc. Logo
Develops nucleic acid vaccines & therapies for infectious diseases, cancer & autoimmune disorders.
South Korea
011000
Generation Bio Co. Logo
Developing siRNA genetic medicines via targeted nanoparticles for autoimmune diseases.
United States of America
GBIO
Genetic Analysis AS Logo
Develops microbiome diagnostics to detect gut dysbiosis for clinical and pharma partners.
Norway
GEAN
GENFIT Logo
Biopharma developing therapies & diagnostics for rare, life-threatening liver diseases.
France
GNFT
Genfit S.A. Logo
Biopharma developing therapeutics and diagnostics for rare and life-threatening liver diseases.
United States of America
GNFT
GEN İLAÇ VE SAĞLIK ÜRÜNLERİ SANAYİ VE TİCARET A.Ş. Logo
Develops and manufactures pharmaceuticals for rare diseases and unmet health needs globally.
Türkiye
GENIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.